VRDN on Nasdaq

Viridian Therapeutics, Inc.\DE

We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with ASSEMBLY BIOSCIENCES, INC., Rockwell Medical Inc. or Bicycle Therapeutics (United Kingdom), or pick any stock.

  • TickerVRDN on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham, Massachusetts1
  • Incorporated inDE2
  • Business address221 Crescent Street, Suite 103A, Waltham, Ma 024532
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients. We aim to develop differentiated, potential best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, and expanded market access.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-512.9%Operating margin4
-483.6%Net margin4
23359.9%Revenue growth, 20254
-47.4%Return on equity4
-$276.9MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

License brought in 99% of the revenue Viridian Therapeutics, Inc.\DE broke down this way in fiscal 2025.

  1. License$70.0M499%
  2. Collaboration$849.0K41%up 181% from 2024
Products and services by year
Products and services202320242025
License$0$0$70.0M
Collaboration$314.0K$302.0K$849.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Selling, general and admin100¢$95.3M

Out of $70.8M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$70.8M in 2025+1488% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $4.5M$4.5M20192020: $1.1M$1.1M2020−76%2021: $3.0M$3.0M2021+182%2022: $1.8M$1.8M2022−40%2023: $314.0K$314.0K2023−82%2024: $302.0K$302.0K2024−4%2025: $70.8M$70.8M2025+23360%
Operating income56784-$363.4M in 2025+766% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$42.0M-$42.0M20192020: -$110.4M-$110.4M2020+163%2021: -$79.7M-$79.7M2021−28%2022: -$134.3M-$134.3M2022+68%2023: -$254.4M-$254.4M2023+89%2024: -$299.0M-$299.0M2024+18%2025: -$363.4M-$363.4M2025+22%
Net income56784-$342.6M in 2025+718% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$41.9M-$41.9M20192020: -$110.7M-$110.7M2020+164%2021: -$79.4M-$79.4M2021−28%2022: -$129.9M-$129.9M2022+64%2023: -$237.7M-$237.7M2023+83%2024: -$269.9M-$269.9M2024+14%2025: -$342.6M-$342.6M2025+27%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Total revenues$70.8M$302.0K$314.0K
Research and development$338.9M$238.3M$159.8M
Selling, general and administrative$95.3M$61.1M$95.0M
Total operating expenses$434.2M$299.3M$254.8M
Loss from operations-$363.4M-$299.0M-$254.4M
Interest income$27.4M$31.6M$18.2M
Interest expense-$4.9M-$2.2M-$1.3M
Other expense, net-$1.7M-$314.0K-$193.0K
Total other income, net$20.8M$29.1M$16.7M
Net loss-$342.6M-$269.9M-$237.7M
Unrealized gain (loss) on available-for-sale securities$457.0K-$348.0K$728.0K
Total other comprehensive income (loss)$457.0K-$348.0K$728.0K
Comprehensive loss-$342.1M-$270.3M-$237.0M

Compare Viridian Therapeutics, Inc.\DE with another company

Leadership

Who has led Viridian Therapeutics, Inc.\DE, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Samuel D. Riccitelli2014–2016
  2. Lee M. Rauch2020
  3. Jonathan Violin2021–2022
  4. Scott Dunseth Myers2023
  5. Stephen F. Mahoney2023–now

President

  1. Samuel D. Riccitelli2014–2016
  2. Lee M. Rauch2020
  3. Jonathan Violin2020–2021
  4. Stephen F. Mahoney2023–now

Chief financial officer

  1. Tamara A. Seymour2014–2016
  2. Jason A. Leverone2017–2021
  3. Kristian Humer2021–2023
  4. Seth Harmon2025–now

Chief operating officer

  1. Lee M. Rauch2020
  2. Jonathan Violin2020
  3. Carrie Melvin2022–2023
  4. Thomas W. Beetham2023–now
201520202025
Board members and other officers (31)

Former names

  • MIRAGEN THERAPEUTICS, INC.Feb 13, 2017 to Jan 15, 20212
  • SIGNAL GENETICS, INC.Dec 6, 2013 to Feb 10, 20172
  • SIGNAL GENETICS LLCNov 12, 2013 to Jul 9, 20142

Timeline

  1. Nov 1, 2023New chief executive Stephen F. Mahoney becomes CEO14
  2. Feb 7, 2023New chief executive Scott Dunseth Myers becomes CEO13
  3. Jan 20, 2021New chief executive Jonathan Violin becomes CEO15
  4. Sep 15, 2020New chief executive Lee M. Rauch becomes CEO16
  5. Jun 17, 2014New chief executive Samuel D. Riccitelli becomes CEO17

Filings

317 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 103 insider forms, 69 large holders, 64 other. The latest 20:

  1. Aug 20, 20264 EDGAR
  2. Aug 20, 2026SCHEDULE 13G EDGAR
  3. Aug 19, 2026144 EDGAR
  4. Aug 18, 20264 EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 14, 2026SCHEDULE 13G EDGAR
  9. Aug 7, 2026SCHEDULE 13G EDGAR
  10. Aug 6, 202610-Q EDGAR
  11. Aug 6, 20268-K EDGAR
  12. Jul 2, 20264 EDGAR
  13. Jul 2, 20264 EDGAR
  14. Jul 2, 20264 EDGAR
  15. Jul 2, 20264 EDGAR
  16. Jul 2, 20264 EDGAR
  17. Jul 2, 20264 EDGAR
  18. Jun 29, 20268-K EDGAR
  19. Jun 26, 2026SCHEDULE 13G EDGAR
  20. Jun 3, 20268-K EDGAR

The 317 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

40 open-market trades by officers, directors and large owners since October 2021: 9 buys and 31 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 19, 2026Tousignant JenniferChief Legal OfficerSale14,212$24.50$348.2KForm 4
May 11, 2026Fairmount Healthcare Fund II L.P.DirectorBuy1,176,470$17.00$20.0MForm 4
Dec 31, 2025Tousignant JenniferChief Legal OfficerSale2,272$31.16$70.8KForm 4
Oct 23, 2025Fairmount Healthcare Fund II GP LLCDirectorBuy454,545$22.00$10.0MForm 4
Sep 27, 2024Beetham Thomas W.Chief Operating OfficerBuy5,000$23.41$117.0KForm 4
Sep 27, 2024Mahoney Stephen F.President and CEOBuy21,400$23.33$499.3KForm 4
Sep 13, 2024Fairmount Healthcare Fund II L.P.DirectorBuy1,600,000$18.75$30.0MForm 4
Jan 22, 2024Fairmount Healthcare Fund II L.P.DirectorBuy476,190$21.00$10.0MForm 4
Jun 16, 2023Meisner LaraChief Legal OfficerSale27$28.35$765Form 4
Jun 15, 2023Meisner LaraChief Legal OfficerSale2,269$28.02$63.6KForm 4
Jun 6, 2023Meisner LaraChief Legal OfficerSale5,126$25.02$128.3KForm 4
Jun 5, 2023Meisner LaraChief Legal OfficerSale499$25.03$12.5KForm 4
Jun 2, 2023Meisner LaraChief Legal OfficerSale1,875$24.21$45.4KForm 4
Apr 12, 2023Myers Scott DunsethChief Executive OfficerBuy4,000$25.37$101.5KForm 4
Mar 13, 2023Myers Scott DunsethChief Executive OfficerBuy5,500$29.15$160.3KForm 4
Mar 9, 2023Meisner LaraChief Legal OfficerSale29,971$29.07$871.3KForm 4
Feb 2, 2023Violin JonathanChief Executive OfficerSale50,000$36.80$1.8MForm 4
Feb 2, 2023Violin JonathanChief Executive OfficerSale50,000$36.80$1.8MForm 4
Jan 23, 2023Meisner LaraChief Legal OfficerSale6,843$35.66$244.0KForm 4
Jan 17, 2023Katz BarrettChief Medical OfficerSale24,853$37.21$924.8KForm 4

All 40 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC16,604,740$305.0M0.0%+1,225,363
BlackRock, Inc.8,551,488$157.1M0.0%+720,013
Bellevue Group AG6,731,909$123.7M2.6%+5,765
Paradigm Biocapital Advisors LP6,723,788$123.5M2.3%+3,574,895
Kynam Capital Management, LP6,453,877$118.6M6.6%+4,112,225
State Street Corp6,124,976$112.5M0.0%+1,452,091
Fairmount Funds Management LLC5,090,928$93.5M6.2%+1,176,470
Vanguard Capital Management LLC4,576,860$84.1M0.0%+409,659
Deep Track Capital, LP3,592,740$66.0M1.0%+2,198,796
Venrock Adviser, LLC3,257,917$59.8M1.8%−624,792
Wellington Management Group Llp3,128,362$57.5M0.0%+49,808
Vanguard Portfolio Management LLC2,752,827$50.6M0.0%+1,111,350
Geode Capital Management, LLC2,501,869$46.0M0.0%+168,656
Avoro Capital Advisors LLC2,500,000$45.9M0.4%+1,000,000
Baker Bros. Advisors LP2,383,025$43.8M0.2%+411,347
Point72 Asset Management, L.P.2,343,208$43.0M0.1%+2,020,372
Caligan Partners LP2,193,981$40.3M1.9%New
Novo Holdings A/s2,135,000$39.2M2.3%+135,000
Tang Capital Management LLC1,792,626$32.9M1.5%No change
Fisher Asset Management, LLC1,750,850$32.2M0.0%−17,445
Candriam S.C.A.1,707,698$31.3M0.1%+995,959
Goldman Sachs Group Inc1,691,304$31.1M0.0%+99,359
First Turn Management, LLC1,670,000$30.7M3.3%+758,663
Dimensional Fund Advisors LP1,611,521$29.6M0.0%+1,081,758
Alliancebernstein L.P.1,391,639$27.2M0.0%−433

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80